Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Merlintrader Education · RunUP Biotech
RunUP Biotech Masterclass
A structured five-chapter course for understanding biotech catalysts, clinical trial data, FDA decisions, valuation, dilution risk and due diligence—without signals, shortcuts or promises of profit.
English edition · Fully revised July 16, 2026
What this masterclass does
A practical framework for reading biotech risk before the market forces the lesson on you
Biotech is one of the few public-market sectors where a single press release can radically change the value of a company. A pivotal trial can validate or destroy a thesis. An FDA decision can unlock a commercial asset or expose manufacturing, safety or benefit-risk problems. A financing can extend a runway while simultaneously changing the value of every existing share.
This masterclass connects those moving parts into one repeatable process. It teaches readers how to identify a catalyst, verify the date, understand the evidence, compare the result with expectations, assess the balance sheet and decide what remains uncertain. The objective is not to predict every outcome. It is to stop confusing a compelling story with a complete analysis.
5In-depth chapters
100%English edition
4Primary-source pillars
1Connected research process
Course map
Five chapters, one analytical chain
Each chapter answers a different question, but they are designed to work together. Reading only the catalyst date without understanding the data, valuation and financing risk is not a complete process.
Biotech Catalyst Trading Guide
Learn how regulatory events, clinical readouts, financings, partnerships, conferences and commercial updates move expectations—and why a catalyst is not automatically bullish or bearish.
Catalyst verification
Run-up lifecycle
Crowding
Event risk
How to Read Clinical Trial Results
Move beyond “endpoint met.” Study trial design, patient population, controls, effect size, confidence intervals, multiplicity, safety, subgroup claims and the difference between statistical and clinical significance.
Phase 1–3
Endpoints
Statistics
Safety
PDUFA Dates, FDA Reviews and CRLs
Understand NDA and BLA reviews, standard versus priority review, advisory committees, labeling, CMC and inspections, approval scenarios, Complete Response Letters and the market risk around target action dates.
FDA review
PDUFA
AdCom
CRL
Biotech Valuation Framework
Build a transparent valuation from patients, penetration, price, revenue ramp, probability of success and operating economics. Then incorporate cash, debt, milestones, royalties, share count and future dilution.
Peak sales
rNPV
Enterprise value
Dilution
Biotech Due Diligence: Red Flags and Green Flags
Combine clinical evidence, regulatory risk, manufacturing, governance, competition, intellectual property, financing and disclosure quality into a repeatable checklist. The final chapter also provides a rapid scan and a full deep-dive workflow.
Due diligence
SEC filings
Governance
Risk map
The RunUP analytical model
The five questions behind every catalyst setup
The course uses a simple chain called the 5E model. It is not a trading signal. It is a way to expose missing work before a position is built around incomplete information.
1EventWhat may happen, and when?
2EvidenceWhat data support the case?
3ExpectationsWhat is already priced in?
4Enterprise valueWhat does the valuation imply?
5ExposureWhat risk is actually being taken?
A catalyst date is not a thesis
A calendar entry tells you that an event may occur. It does not tell you whether the evidence is strong, whether the event is already anticipated, whether financing is likely before or after it, or whether the potential reward compensates for the downside. The rest of the masterclass exists to answer those questions.
How to study
Choose the pace that matches the depth you need
Five-day intensive
Read one chapter per day. At the end of each chapter, apply its checklist to one live company without taking any action. The exercise is analysis, not execution.
Two-week research track
Read each chapter, then spend one or two sessions checking the same topic in primary documents. This is the best format for readers building a repeatable workflow.
Reference mode
Return directly to the relevant chapter when a trial, PDUFA date, financing or valuation question appears. The pages are structured to work as evergreen reference guides.
Source discipline
Where the research should begin
Biotech information is frequently repeated, simplified and distorted as it moves from an official document to a headline and then to social media. This course treats primary documents as the starting point.
FDA
Drug-development guidance, review pathways, approval documents, advisory materials and safety communications.
Open FDA drug development resources
ClinicalTrials.gov
Study design, enrollment, endpoints, status, locations and disclosed protocol information.
Search ClinicalTrials.gov
SEC EDGAR
Cash, burn, offerings, shelves, warrants, debt, insider filings, risk factors and material company disclosures.
Search SEC filings
Company investor relations
Full press releases, earnings materials, presentations and conference-call commentary—checked against filings and regulators.
Open the Merlintrader Biotech Tools Hub
Use social platforms as a sentiment layer, not an evidence layer
Reddit, Stocktwits and X can reveal attention, positioning and popular narratives. They cannot replace a protocol, an FDA document, a filing or a complete data table. A confident post is not a primary source.
What readers should be able to do
Learning outcomes
Verify the event
- Separate confirmed dates from estimated windows.
- Trace a catalyst back to the strongest available source.
- Identify events that may slip, extend or change form.
Read the substance
- Distinguish statistical success from clinical relevance.
- Recognize safety, CMC and regulatory risks.
- Compare a result with expectations and competitors.
Map the equity risk
- Calculate enterprise value and a realistic cash runway.
- Identify shelf, ATM, warrant and debt dilution paths.
- Build bull, base and bear scenarios without presenting them as certainty.
Boundaries
What this course is—and what it is not
It is an educational research framework
The masterclass explains how market participants may analyze catalyst-driven biotech securities, how to verify information and how to identify uncertainty. It can support independent research and help readers ask better questions.
It is not a recommendation, signal service or promise of profit
No chapter tells readers to buy, sell or hold a security. No framework eliminates binary risk, gaps, dilution, liquidity problems or analytical error. Personal financial circumstances, time horizon and risk capacity are outside the scope of this publication.
Frequently asked questions
Before you begin
Is the RunUP Biotech Masterclass free?
Yes. The course is published as free educational content on Merlintrader. Readers who find it useful can support the project by sharing it, joining the community or making a voluntary contribution through the support options available on the site.
Does “RunUP” mean holding through a binary event?
No. RunUP Biotech refers to studying the period in which attention, expectations, liquidity and positioning may develop before a catalyst. Whether a person holds, reduces or avoids exposure is a separate risk decision. The course does not prescribe an execution strategy.
Can a confirmed catalyst date still change?
Yes. Trial readouts can move within guidance windows, regulatory target dates can be extended, conference schedules can change and companies can revise timelines. Dates should be checked repeatedly against official sources.
Does a positive trial always produce a positive stock reaction?
No. The reaction depends on the details, prior expectations, valuation, safety, competitive differentiation, financing needs and positioning. A technically positive result can disappoint if the market expected more.
Why does the valuation chapter include dilution?
Because company value and per-share value are not the same. A program can progress while an expanding share count, warrants, convertibles or new offerings alter the outcome for existing shareholders.
Where should a beginner start?
Begin with Chapter 1, then follow the sequence. Keep the Catalyst Calendar, Biotech Tools Hub and primary-source sites open while reading.
Start with the event—but finish with the full risk map
Chapter 1 explains how to identify, verify and classify biotech catalysts before evaluating the evidence, expectations and exposure around them.
Educational and legal notice. Merlintrader publishes independent informational and educational content. Nothing on this page constitutes investment advice, personalized financial advice, a recommendation, an offer or solicitation to buy or sell securities, or regulated research. Biotech and small-cap securities can be highly volatile, illiquid and exposed to clinical, regulatory, financing and dilution risk. Information may become outdated or prove incomplete. Verify material facts through official FDA, SEC, ClinicalTrials.gov and company sources and consult a properly authorized professional where appropriate. Read the full Disclaimer & Risk Disclosure.
